Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
This multicenter registry study aims to analyze time-related changes in the treatment patterns and outcome of patients with metastatic breast cancer (MBC) over a ten-year period. Correlations between demographic, prognostic variables and survival outcomes were carried out in database aggregates cons...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/6/1667 |
| _version_ | 1797613027571269632 |
|---|---|
| author | Izzet Dogan Sercan Aksoy Burcu Cakar Gul Basaran Ozlem Ercelep Nil Molinas Mandel Taner Korkmaz Erhan Gokmen Cem Sener Adnan Aydiner Pinar Saip Yesim Eralp |
| author_facet | Izzet Dogan Sercan Aksoy Burcu Cakar Gul Basaran Ozlem Ercelep Nil Molinas Mandel Taner Korkmaz Erhan Gokmen Cem Sener Adnan Aydiner Pinar Saip Yesim Eralp |
| author_sort | Izzet Dogan |
| collection | DOAJ |
| description | This multicenter registry study aims to analyze time-related changes in the treatment patterns and outcome of patients with metastatic breast cancer (MBC) over a ten-year period. Correlations between demographic, prognostic variables and survival outcomes were carried out in database aggregates consisting of cohorts based on disease presentation (recurrent vs. de novo) and the diagnosis date of MBC (Cohort I: patient diagnosed between January 2010 and December 2014; and Cohort II: between January 2015 and December 2019). Out of 1382 patients analyzed, 52.3% patients had recurrent disease, with an increased frequency over time (47.9% in Cohort I vs. 56.1% in Cohort II, <i>p</i> < 0.001). In recurrent patients, 38.4% (<i>n</i> = 277) relapsed within two years from initial diagnosis, among which triple-negative BC (TNBC) was the most frequent (51.7%). Median overall survival (OS) was 51.0 (48.0–55.0) months for all patients, which was similar across both cohorts. HER2+ subtype had the highest OS among subgroups (HER2+ vs. HR+ vs. TNBC; 57 vs. 52 vs. 27 months, <i>p</i> < 0.001), and the dnMBC group showed a better outcome than recMBC (53 vs. 47 months, <i>p</i> = 0.013). Despite the lack of CDK inhibitors, luminal A patients receiving endocrine therapy had a favorable outcome (70 months), constituting an appealing approach with limited resources. The only survival improvement during the timeframe was observed in HER2+ dnMBC patients (3-year OS Cohort I: 62% vs. Cohort II: 84.7%, <i>p</i> = 0.009). The incorporation of targeted agents within standard treatment has improved the outcome in HER2+ MBC patients over time. Nevertheless, despite advances in early diagnosis and treatment, the prognosis of patients with TNBC remains poor, highlighting the need for more effective treatment options. |
| first_indexed | 2024-03-11T06:50:09Z |
| format | Article |
| id | doaj.art-efe4617b8ad84df7bdeac0960f3c68ad |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T06:50:09Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-efe4617b8ad84df7bdeac0960f3c68ad2023-11-17T10:05:32ZengMDPI AGCancers2072-66942023-03-01156166710.3390/cancers15061667Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology GroupIzzet Dogan0Sercan Aksoy1Burcu Cakar2Gul Basaran3Ozlem Ercelep4Nil Molinas Mandel5Taner Korkmaz6Erhan Gokmen7Cem Sener8Adnan Aydiner9Pinar Saip10Yesim Eralp11Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, TurkeyDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, TurkeyDepartment of Medical Oncology, Acibadem University, Altunizade Acibadem Hospital, Istanbul 34662, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul 34722, TurkeyDepartment of Medical Oncology, Koç University Amerikan Hospital, Istanbul 34010, TurkeyDepartment of Medical Oncology, Acibadem University, Maslak Acibadem Hospital, Istanbul 34457, TurkeyDepartment of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, TurkeyIncidence Medical Research and Biostatistics Consultancy Services, Istanbul 34440, TurkeyDepartment of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, TurkeyDepartment of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, TurkeyResearch Institute of Senology, Acıbadem University, Maslak Acıbadem Hospital, Istanbul 34457, TurkeyThis multicenter registry study aims to analyze time-related changes in the treatment patterns and outcome of patients with metastatic breast cancer (MBC) over a ten-year period. Correlations between demographic, prognostic variables and survival outcomes were carried out in database aggregates consisting of cohorts based on disease presentation (recurrent vs. de novo) and the diagnosis date of MBC (Cohort I: patient diagnosed between January 2010 and December 2014; and Cohort II: between January 2015 and December 2019). Out of 1382 patients analyzed, 52.3% patients had recurrent disease, with an increased frequency over time (47.9% in Cohort I vs. 56.1% in Cohort II, <i>p</i> < 0.001). In recurrent patients, 38.4% (<i>n</i> = 277) relapsed within two years from initial diagnosis, among which triple-negative BC (TNBC) was the most frequent (51.7%). Median overall survival (OS) was 51.0 (48.0–55.0) months for all patients, which was similar across both cohorts. HER2+ subtype had the highest OS among subgroups (HER2+ vs. HR+ vs. TNBC; 57 vs. 52 vs. 27 months, <i>p</i> < 0.001), and the dnMBC group showed a better outcome than recMBC (53 vs. 47 months, <i>p</i> = 0.013). Despite the lack of CDK inhibitors, luminal A patients receiving endocrine therapy had a favorable outcome (70 months), constituting an appealing approach with limited resources. The only survival improvement during the timeframe was observed in HER2+ dnMBC patients (3-year OS Cohort I: 62% vs. Cohort II: 84.7%, <i>p</i> = 0.009). The incorporation of targeted agents within standard treatment has improved the outcome in HER2+ MBC patients over time. Nevertheless, despite advances in early diagnosis and treatment, the prognosis of patients with TNBC remains poor, highlighting the need for more effective treatment options.https://www.mdpi.com/2072-6694/15/6/1667breast cancermetastasistreatmenthuman epidermal growth factor receptor 2hormone receptorregistries |
| spellingShingle | Izzet Dogan Sercan Aksoy Burcu Cakar Gul Basaran Ozlem Ercelep Nil Molinas Mandel Taner Korkmaz Erhan Gokmen Cem Sener Adnan Aydiner Pinar Saip Yesim Eralp Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group Cancers breast cancer metastasis treatment human epidermal growth factor receptor 2 hormone receptor registries |
| title | Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group |
| title_full | Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group |
| title_fullStr | Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group |
| title_full_unstemmed | Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group |
| title_short | Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group |
| title_sort | demographic and clinical features of patients with metastatic breast cancer a retrospective multicenter registry study of the turkish oncology group |
| topic | breast cancer metastasis treatment human epidermal growth factor receptor 2 hormone receptor registries |
| url | https://www.mdpi.com/2072-6694/15/6/1667 |
| work_keys_str_mv | AT izzetdogan demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT sercanaksoy demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT burcucakar demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT gulbasaran demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT ozlemercelep demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT nilmolinasmandel demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT tanerkorkmaz demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT erhangokmen demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT cemsener demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT adnanaydiner demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT pinarsaip demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup AT yesimeralp demographicandclinicalfeaturesofpatientswithmetastaticbreastcanceraretrospectivemulticenterregistrystudyoftheturkishoncologygroup |